RVO

Central retinal artery occlusion is characterized by painless, sudden vision loss in one eye, which may be a sign of an eye stroke.

According to the company, the deals from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

According to Roche, faricimab (Vabysmo)showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies.

Eye drops developed by Columbia University researchers could prove to be a more effective and comfortable therapy for retinal vein occlusion (RVO).

If approved, RVO would be the third indication for faricimab-svoa in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

A large cohort study found no association between the first messenger RNA COVID-19 vaccinations and acute retinal vein occlusions.